Lilly explains accelerated development goals

The changes being contemplated by Eli Lilly and Co.'s management, if the company can pull them off, should be a plus for Lilly's current and future biotech partners. The company said last week that it hopes to cut by up to 50 percent the time it takes between the beginning of the formal drug development process and the